Advertisement

Topics

Search Results for "President CEO Epicentre Biotechnologies"

00:20 EDT 28th March 2017 | BioPortfolio

Matching Channels

Drug Development for Rare Diseases

The economics of any industry relies on a large demand for a particular product; this applies to the pharmaceutical industry where efforts are focused on big and relatively straight-forward diseases...

Matching News

Lion Biotechnologies to Present at the 28th Annual Piper Jaffray Healthcare Conference

SAN CARLOS, CA--(Marketwired - November 23, 2016) - Lion Biotechnologies, Inc. (NASDAQ: LBIO), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte te...

Mount Tam Biotechnologies, Inc., to present at Bio CEO Investor Conference

NOVATO, CA--(Marketwired - Feb 9, 2017) - Mount Tam Biotechnologies, Inc. ("Mount Tam") ( OTC PINK : MNTM), a company focused on the Read more...

Elanix Biotechnologies AG Announces Non-Binding Letter of Intent with Oxford MEstar Ltd. ...

Elanix Biotechnologies AGMaria WidowskiE-mail: investor.relations@elanix-bt.comPhone number: +49 331 583 945 10 Read more...

Elanix Biotechnologies: Erfolgreiche Finanzierungsrunde

Elanix Biotechnologies hat eine Kapitalerhöhung erfolgreich abgeschlossen. Insgesamt werden 1,133 Millionen Aktien ausgegeben. Der Bezugspreis je Aktie liegt bei 4,20 Euro. Somit kommen brutto 4,76.....

BRIEF-Lion biotechnologies reports qtrly loss per share of $1.15

* Lion Biotechnologies reports third quarter 2016 financial results and provides corporate update

Lion Biotechnologies to Present at Upcoming Investor Conferences in March

SAN CARLOS, CA--(Marketwired - February 27, 2017) - Lion Biotechnologies, Inc. (NASDAQ: LBIO), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (...

Lion Biotechnologies Harnesses TIL Technology to Attack Cancers

ArticleImmunotherapy is one of the biggest things in oncology at the moment and San Francisco-based Lion Biotechnologies Inc., is pushing ahead using tumor-infiltrating lymphocytes (TIL) to destroy so...

WuXi AppTec inks new manufacturing services agreement with Lion Biotechnologies

Lion Biotechnologies has expanded its ‘favorable’ existing relationship with WuXi AppTec to manufacture its autologous cell therapy products.

Matching PubMed Articles

President's Editorial -A President's Insight into the AAFS.

The choices we make as teachers.

"She wasn't like you...wasn't like any politician I've ever known." Ethan Kanin, Secretary of State about US president Allison Taylor in the US serial, 24. When an ethical dilemma arises, the choices ...

Momir H. Polenakovic - Founder of the Nephrology Associations in the Republic of Macedonia.

Acad. Momir Polenakovic has devoted his life and work in the diagnosis and treatment of kidney patients, as well as in research of kidney disease. The great experience he has acquired in the work with...

Nurses on Boards: My Experience on the Moonshot.

Being a member-and the only nurse-of the Blue Ribbon Panel on Vice President Joe Biden's National Cancer Moonshot Initiative, announced during President Barack Obama's State of the Union Address, I ha...

Reliability of noncontrast-enhancing tumor as a biomarker of IDH1 mutation status in glioblastoma.

Isocitrate dehydrogenase 1 (IDH1) mutations in gliomas have been associated with a frontal lobe location and a greater proportion of noncontrast-enhancing tumour (nCET). The purpose of our study was t...

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement